Artificial blood could reduce preventable deaths in settings where limited supply costs millions of lives in low-income ...

Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date ...

Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human ...

COST’s governing board, the Committee of Senior Officials (CSO) approved funding for seven new COST Innovators Grants (CIGs).

Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoin ...